Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | -- |
Average volume | -- |
---|---|
Shares outstanding | 76.92m |
Free float | 74.92m |
P/E (TTM) | -- |
Market cap | 3.41bn USD |
EPS (TTM) | -5.94 USD |
Data delayed at least 15 minutes.
More ▼
Press releases
- PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
- PTC Therapeutics to Participate at Upcoming Investor Conferences
- PTC Therapeutics Announces FDA Acceptance of Translarna™ NDA Resubmission
- PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2024 Financial Results
- CHMP Maintains Negative Opinion on Translarna™ Reexamination
- PTC Therapeutics Announces FDA Target Regulatory Action Date for Sepiapterin and Lancet Publication of Phase 3 Trial Results
- PTC Therapeutics Announces Positive Results from Long-Term Treatment Studies and Updates on Regulatory Progress for Vatiquinone Friedreich Ataxia Program
- PTC Therapeutics Announces FDA Acceptance for Filing of NDA for Sepiapterin for the Treatment of Pediatric and Adult Phenylketonuria Patients
- FDA Grants Fast Track Designation to PTC518 Huntington's Disease Program
More ▼